Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.
PBT, proton beam therapy
RAI, radioactive iodine 125 implant
UM, uveal melanoma
Journal
Mayo Clinic proceedings. Innovations, quality & outcomes
ISSN: 2542-4548
Titre abrégé: Mayo Clin Proc Innov Qual Outcomes
Pays: Netherlands
ID NLM: 101728275
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
To review the current state of radiation therapy for uveal melanoma and compare particle radiation and brachytherapy. The medical records of 156 patients treated for uveal melanoma between May 30, 2012, and March 16, 2020, were retrospectively reviewed. Treatments consisted of either radioactive iodine 125 implant (RAI) or fractionated proton radiation (proton beam therapy [PBT]). Baseline characteristics were compared using a Wilcoxon rank sum test or χ The median length of follow-up after treatment was 2.7 years (range, 0.5 to 9.0 years). Patients who underwent treatment with RAI were older (median age, 67 vs 59 years; Treatment with PBT and RAI has similar efficacy; however, there are differences in the adverse outcomes associated with these 2 modalities.
Identifiants
pubmed: 35005435
doi: 10.1016/j.mayocpiqo.2021.10.002
pii: S2542-4548(21)00154-5
pmc: PMC8715138
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-36Informations de copyright
© 2021 The Authors.
Références
Ophthalmic Res. 2006;38(5):255-60
pubmed: 16888407
Acta Ophthalmol. 2017 Dec;95(8):e727-e733
pubmed: 27914117
Ophthalmology. 1993 Oct;100(10):1547-54
pubmed: 8414414
Br J Ophthalmol. 2008 Jun;92(6):727-8
pubmed: 18523075
Mayo Clin Proc. 1993 Dec;68(12):1196-200
pubmed: 8246622
Am J Ophthalmol. 1977 May;83(5):665-73
pubmed: 405869
J Contemp Brachytherapy. 2020 Aug;12(4):303-310
pubmed: 33293968
Arch Ophthalmol. 2000 Sep;118(9):1219-28
pubmed: 10980767
Radiat Oncol. 2020 Jul 29;15(1):183
pubmed: 32727533
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Cancer. 1998 Oct 15;83(8):1664-78
pubmed: 9781962
Arch Ophthalmol. 2001 Jul;119(7):969-82
pubmed: 11448319
BMC Cancer. 2020 Jun 26;20(1):599
pubmed: 32590957
Cancer. 2005 Mar 1;103(5):1000-7
pubmed: 15651058
Stat Methods Med Res. 1996 Sep;5(3):311-29
pubmed: 8931198
Br J Ophthalmol. 2020 Jul;104(7):885-886
pubmed: 32434774
Eur J Cancer. 2015 Nov;51(16):2404-12
pubmed: 26278648
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Arch Ophthalmol. 2000 Jun;118(6):773-8
pubmed: 10865313
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Am J Ophthalmol. 2018 Nov;195:154-160
pubmed: 30092184
Cancer. 2016 May 15;122(10):1483-501
pubmed: 26828647
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
Eur Urol. 2017 Nov;72(5):712-735
pubmed: 28366513
Clin Ophthalmol. 2018 May 17;12:925-934
pubmed: 29844657
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):18-26
pubmed: 23040219
Clin Oncol (R Coll Radiol). 2016 Mar;28(3):198-203
pubmed: 26385821
Control Clin Trials. 1993 Oct;14(5):362-91
pubmed: 8222668
Retina. 2019 Jun;39(6):1154-1164
pubmed: 29578940
PLoS One. 2015 May 18;10(5):e0127814
pubmed: 25993284
JAMA Ophthalmol. 2015 Jul;133(7):792-6
pubmed: 25905597
Am J Clin Oncol. 2021 Jan 1;44(1):32-42
pubmed: 33208706
Ocul Oncol Pathol. 2020 May;6(3):210-218
pubmed: 32509767
Phys Med Biol. 2019 Jan 24;64(3):035010
pubmed: 30566923
Retina. 2018 Feb;38(2):211-219
pubmed: 28665870
Brachytherapy. 2018 Mar - Apr;17(2):432-438
pubmed: 29275868
Eur J Ophthalmol. 2018 Nov;28(6):722-730
pubmed: 29788760
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Ocul Oncol Pathol. 2017 Sep;3(3):193-198
pubmed: 29071269
Middle East Afr J Ophthalmol. 2010 Jul;17(3):210-6
pubmed: 20844676